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PHAGE DISPLAY: AN APPROXIMATION TO CANCER-TARGETED 
NANOMEDICINES 
Nowadays, the prevalence of cancer is a worldwide public health burden. The current treatments suffer from a lack of specificity and selectivity. For that reason, it is necessary 
to provide alternatives to target cancer treatment to malignant cells exclusively and make it become less aggressive.  
 INTRODUCTION 
 MATERIAL AND METHODS 
 Choice of phage: filamentous (Fig. 2), T4, T7 or lambda 
 Type of coat protein: there are three structural proteins on M13 that have been used as vehicles for peptide 
libraries. The most common by far is pIII, followed by pVIII (Fig. 2) 
 Type of ligand displayed: peptide libraries or antibody libraries 
 Full or hybrid display: it determines whether all the copies of the coat protein will display the ligand  (full 
display) or only a few of them (hybrid display). 
 Insert location: the mutant gene can be encoded in the phage genome or in a phagemid (Fig. 3). 
Taking into account all those parameters, it will be possible to develop different types of display (shown in Table 1).  
1. Target immobilization: for example in a solid support (96-well polystyrene microtiter plates).   
2. Phage binding: the library is added to the target coated well.   
3. Washing: unbound bacteriophages are removed. The first round of biopanning requires higher yield of 
the fittest phage clones over the background and hence the washes are less stringent.  
4. Phage elution: adding for example a solution containing either free target or a competing ligand.  
•Phage display is a valuable tool in biomedical applications which offers rapid, efficient and relatively inexpensive methods. The outstanding advantage of this 
technique is the ability to generate an enormously diverse exogenous peptides or proteins displayed on the surface of the phage using standard rapid molecular 
methods.  
•Peptide-mediated targeting liposomes offer several advantages over the use of free drugs in treatment of breast cancer. Furthermore, the modification of 
existing liposomes with phage protein provides liposomes with the ability to bind target cells stronger compared to the non-modified liposomes.  
•To sum up, phage display is a powerful technique that can be very useful in the near future, although it has to be studied in depth in order to improve some 
weak points.   
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 RESULTS 
Peptides isolated from phage-displayed libraries can be used as targeting molecules 
for many applications: radiolabeled peptides, peptides conjugated with 
chemotherapeutic agents and peptides on nanoparticles or liposomes carrying 
chemotherapeutic agents (5).  
 
For instance, doxorubicin-loaded liposomes (Doxil) have been modified with a phage 
fusion coat protein specific towards MCF-7 breast cancer cells (Fig. 5). MCF-7-phage-
Doxil demonstrated a significantly enhanced association with target cells and an 
increased cytotoxicity. In conclusion, the incorporation of such phage protein into 
doxorubicin-loaded liposomes resulted in a remarkable increase in the killing 
efficiency of targeted tumour cells.  
Library construction 
 
Screening and selection  
 
Finally, the eluted phage is amplified in bacteria (by infecting Escherichia coli). The phage clones obtained 
are analysed by DNA sequencing to identify the target binding peptides.  
Figure 2  Structure of a filamentous bacteriophage particle (the 
copy number of each protein is shown in brackets) (2). 
The screening method (Fig. 4) enriches the phage clones that bind to the target of interest by a process called biopanning (4, 5), which involves the following steps:  
 
DISPLAY TYPE COAT PROTEIN 
DISPLAYED 
FULL OR HYBRID 
DISPLAY 
FUSION  
POSITION  
Type 3 pIII Full Phage genome 
Type 8 pVIII Full Phage genome 
Type 33 pIII Hybrid Phage genome 
Type 88 pVIII Hybrid Phage genome 
Type 3+3 pIII Hybrid Phagemid 
Type 8+8 pVIII Hybrid Phagemid 
Figure 3 Use of a phagemid vector and a helper phage to produce a hybrid 
display (the black square represents the gene that encodes the ligand and 
the black circle represents  the ligand displayed) (Adapted from 3). 
Table 1 Classification of most of the common phage display vectors (7)  
Figure 4. Representation of the biopanning process designed to enrich the 
phage that binds specifically to the target. All the steps must be repeated 
three to six times, until sufficient enrichment has occurred (Adapted from 6) 
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Figure 5 Production of a targeted liposome by 
insertion of a phage fusion coat protein into its 
membrane. The pink circles placed in the 
hydrophilic pocket represent the drug administered, 
in this case doxorubicin (8). 
Figure 6  Correlation between doxorubicin uptake and 
cytotoxicity of Doxil ® and MCF-7-phage-Doxil. (A) 
Uptake of doxorubicin by MCF-7 cells. (B) Cytotoxicity of 
Doxil and MCF-7-phage–Doxil towards MCF-7 cells  (8).  
Figure 1  Phage display library. This 
illustration represents the linkage 
between genotype and phenotype 
(Adapted from 1).  
The best alternative is phage display, a method for presenting polypeptides on the 
surface of bacteriophages. This technology is based on a direct linkage between 
phage phenotype and its encapsulated genotype, which leads to presentation of 
molecule libraries fused with the coat proteins on the phage surface. The phage 
display technique allows the creation of libraries (Fig. 1) which contain up to 1010 
different variants.  
The aim of this review is to provide the necessary knowledge to understand the basis and potential of the phage display technique. Furthermore, it focuses on the 
development of a targeted drug therapy against cancer cells using the specific peptides obtained by phage display.    
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